Clinical trial
Gene Therapy for Chronic Granulomatous Disease
NCT00394316 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00394316 |
|---|---|
| Title | Gene Therapy for Chronic Granulomatous Disease |
| Official title | Autologous Transplantation of Genetically Modified Cells for the Treatment of X-Linked Chronic Granulomatous Disease |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Terminated |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Granulomatous Disease |
| Intervention type | Drug |
| Interventions | Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells |
| Enrollment | 3 |
| Start date | Oct 30, 2006 |
| Primary completion | Apr 8, 2014 |
| Completion | Apr 8, 2014 |
| First posted | Nov 1, 2006 |
| Last update posted | Jul 5, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: